The scientist’s investigation covers issues in Internal medicine, Surgery, Sarcoma, Oncology and Pathology. His work on Internal medicine is being expanded to include thematically relevant topics such as Gastroenterology. His work is dedicated to discovering how Surgery, Clinical trial are connected with Discontinuation and other disciplines.
His Sarcoma research is multidisciplinary, incorporating elements of Soft tissue, Cancer research, Prospective cohort study and Leiomyosarcoma. In his study, which falls under the umbrella issue of Oncology, Renal cell carcinoma is strongly linked to Carcinoma. His Pathology research incorporates themes from Biomarker, Targeted therapy and Interleukin 10.
Jean-Yves Blay spends much of his time researching Internal medicine, Oncology, Sarcoma, Surgery and Cancer. His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Soft tissue sarcoma. Jean-Yves Blay works mostly in the field of Oncology, limiting it down to topics relating to Placebo and, in certain cases, Regorafenib.
His Sarcoma study incorporates themes from Cancer research, Incidence, Soft tissue and Leiomyosarcoma. His study connects Hazard ratio and Surgery. The Cancer study combines topics in areas such as Immunology and Family medicine.
Jean-Yves Blay mainly focuses on Internal medicine, Sarcoma, Oncology, Cancer research and Soft tissue sarcoma. His Cancer, Clinical trial and Clinical endpoint study in the realm of Internal medicine connects with subjects such as In patient. His Sarcoma study combines topics from a wide range of disciplines, such as Retrospective cohort study, Incidence, Chemotherapy and Hazard ratio.
His studies in Hazard ratio integrate themes in fields like Surgery, Proportional hazards model and Leiomyosarcoma. His work carried out in the field of Oncology brings together such families of science as Gemcitabine, GiST, Phases of clinical research and Doxorubicin. He has researched Cancer research in several fields, including Immune checkpoint, Immunohistochemistry, Carcinogenesis, Gene and Immune system.
His primary scientific interests are in Internal medicine, Sarcoma, Oncology, Clinical endpoint and Clinical trial. As part of his studies on Internal medicine, Jean-Yves Blay often connects relevant areas like Soft tissue sarcoma. His Sarcoma research incorporates themes from Gastroenterology, Radiation therapy, Retrospective cohort study and Hazard ratio.
His research in Oncology intersects with topics in Gemcitabine, Chemotherapy, Doxorubicin, Anthracycline and Leiomyosarcoma. His study in Clinical endpoint is interdisciplinary in nature, drawing from both Placebo, Adverse effect, Phases of clinical research and Performance status. While the research belongs to areas of Clinical trial, Jean-Yves Blay spends his time largely on the problem of Survival rate, intersecting his research to questions surrounding Prospective cohort study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial*
Jaap Verweij;Paolo G. Casali;John Zalcberg;Axel LeCesne.
The Lancet (2004)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T A Van Der Graaf;Jean Yves Blay;Sant P. Chawla;Dong Wan Kim.
The Lancet (2012)
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman;Igor Puzanov;Vivek Subbiah;Jason E. Faris.
The New England Journal of Medicine (2015)
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D Demetri;Peter Reichardt;Yoon-Koo Kang;Jean-Yves Blay.
The Lancet (2013)
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
George D. Demetri;Robert S. Benjamin;Charles D. Blanke;Jean Yves Blay.
Journal of The National Comprehensive Cancer Network (2007)
Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO
Jean Yves Blay;Sylvie Bonvalot;Paolo Casali;Haesun Choi.
Annals of Oncology (2005)
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner
Francois Ghiringhelli;Cédric Ménard;Magali Terme;Caroline Flament.
Journal of Experimental Medicine (2005)
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
Maria Debiec-Rychter;Raf Sciot;Axel Le Cesne;Marcus Schlemmer.
European Journal of Cancer (2006)
Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
Carola H. Ries;Michael A. Cannarile;Sabine Hoves;Jörg Benz.
Cancer Cell (2014)
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer―Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
Stefan Sleijfer;Isabelle Ray-Coquard;Zsuzsa Papai;Axel Le Cesne.
Journal of Clinical Oncology (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: